S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
LON:HIK

Hikma Pharmaceuticals (HIK) Share Price, News & Analysis

GBX 1,786
-21.00 (-1.16%)
(As of 04/16/2024 ET)
Today's Range
1,760
1,797
50-Day Range
1,778.66
2,083
52-Week Range
1,711
2,222
Volume
514,672 shs
Average Volume
426,310 shs
Market Capitalization
£3.96 billion
P/E Ratio
2,665.67
Dividend Yield
3.19%
Price Target
GBX 2,068.75

Hikma Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
15.8% Upside
GBX 2,068.75 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
-0.08mentions of Hikma Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.82 out of 5 stars

HIK stock logo

About Hikma Pharmaceuticals Stock (LON:HIK)

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.

HIK Stock Price History

HIK Stock News Headlines

HKMPY Hikma Pharmaceuticals PLC
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
European Stocks Close Lower Amid Uncertainty About Interest Rates
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
FTSE 100 Closes Up 0.12% Ahead of U.K. Jobs Data
Hikma beats profit estimates thanks to narcolepsy drug
Hikma Pharmaceutical FY EPS 85c
See More Headlines
Receive HIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 5/3 Dividend
3/21/2024
Today
4/17/2024
Dividend Payable
5/03/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
9,100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 2,068.75
High Stock Price Target
GBX 2,150
Low Stock Price Target
GBX 2,000
Potential Upside/Downside
+15.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
£190 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£2.88 billion
Cash Flow
GBX 214.18 per share
Book Value
GBX 994 per share

Miscellaneous

Free Float
N/A
Market Cap
£3.96 billion
Optionable
Not Optionable
Beta
0.45
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Engineer Said Samih Taleb Darwazah (Age 67)
    Executive Chairman
    Comp: $2.25M
  • Mr. Riad Ali Mishlawi (Age 60)
    CEO & Director
    Comp: $885.46k
  • Mr. Mazen Samih Taleb Darwazah (Age 66)
    Executive Vice Chairman & President of MENA
    Comp: $1.85M
  • Mr. Khalid Waleed Hosny Al Nabilsi (Age 52)
    Chief Financial Officer
  • Patricia Bousfield
    Chief Information Officer
  • Mr. Guy Featherstone
    Associate Director of Investor Relations
  • Mr. Samuel Park
    General Counsel
  • Mr. Bassam Wael Rushdi Kanaan CFA (Age 59)
    CPA, Executive Vice President of Corporate Development and M&A
  • Mr. Hussein Omar Arkhagha
    Chief People Officer
  • Ms. Susan Ringdal
    Executive Vice President of Strategic Planning & Global Affairs

HIK Stock Analysis - Frequently Asked Questions

Should I buy or sell Hikma Pharmaceuticals stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HIK shares.
View HIK analyst ratings
or view top-rated stocks.

What is Hikma Pharmaceuticals' stock price target for 2024?

6 Wall Street research analysts have issued 1-year target prices for Hikma Pharmaceuticals' shares. Their HIK share price targets range from GBX 2,000 to GBX 2,150. On average, they predict the company's share price to reach GBX 2,068.75 in the next twelve months. This suggests a possible upside of 15.8% from the stock's current price.
View analysts price targets for HIK
or view top-rated stocks among Wall Street analysts.

How have HIK shares performed in 2024?

Hikma Pharmaceuticals' stock was trading at GBX 1,789 at the beginning of the year. Since then, HIK shares have decreased by 0.2% and is now trading at GBX 1,786.
View the best growth stocks for 2024 here
.

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals declared a dividend on Thursday, February 22nd. Shareholders of record on Thursday, March 21st will be given a dividend of GBX 0.47 per share on Friday, May 3rd. This represents a dividend yield of 1.86%. The ex-dividend date of this dividend is Thursday, March 21st. This is an increase from the stock's previous dividend of GBX 0.25. The official announcement can be viewed at this link.
Read our dividend analysis for HIK
.

Is Hikma Pharmaceuticals a good dividend stock?

Hikma Pharmaceuticals (LON:HIK) pays an annual dividend of GBX 57 per share and currently has a dividend yield of 3.03%. The dividend payout ratio is 8,507.46%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for HIK.

What other stocks do shareholders of Hikma Pharmaceuticals own?
How do I buy shares of Hikma Pharmaceuticals?

Shares of HIK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:HIK) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners